WSTAM
ARMP icon

Wilbanks Smith & Thomas Asset Management’s Armata Pharmaceuticals ARMP Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio ARMP Stock Details ARMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-71
Closed -$1K – 408
2018
Q3 		$1K Buy
+71
New +$1.04K ﹤0.01% 1485

Other funds holding ARMP

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SXL
Summit X LLC Chesterfield, Missouri $536M AUM 15.36% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's ARMP Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Armata Pharmaceuticals (ARMP) in Q4 2018, closing a stake of 71 shares — an estimated $1K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in ARMP in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 24 funds tracked by Wall St. Rank hold ARMP as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Armata Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 71 Armata Pharmaceuticals shares in Q4 2018, an estimated $1K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Armata Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Armata Pharmaceuticals position peaked at $1K in Q3 2018.
  • 24 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.